Dikai Medical Secures Nearly RMB 100 Million in Series C Funding to Advance Digital Full-Process Solutions for Dental Implant Surgery

VCBeat Learns Firsthand, Suzhou DCARER Medical Technology Co., Ltd. (hereinafter referred to as“DCARER”) announced the completion of a nearly RMB 100 millionCround of financing. This round was led by Hengxu Capital, with follow-on investment from existing shareholder Huiding Capital. Dianshi Capital served as the exclusive financial advisor. The proceeds from this financing round will be used to expand the team, advance market channel development, and broaden the product pipeline.

DCARER, established in 2010, is a high-tech medical device company specializing in the research, development, and industrialization of surgical navigation robots. At present, the company has developed a portfolio of core products centered on dental implant surgery, and plans to further expand into other clinical specialties based on its navigation robot platform.

China’s dental industry still faces significant supply-side deficiencies, which affect the standardization of clinical workflows as well as outcomes such as surgical safety and efficacy. Both public hospitals and private clinics urgently need to improve operational efficiency, with digitalization and intelligence emerging as key development directions. This trend is driving the widespread adoption of computer-assisted navigation technology, particularly in the field of dental implantology. Dynamic visual navigation systems significantly enhance patient experience through minimally invasive procedures and improved safety, substantially boost the efficiency of general practitioners, and provide comprehensive coverage of indications for dental implant surgery, thereby meeting patients’ diverse diagnostic and treatment needs.

According to reports, DCARER has established a professional dental team with an average of over 15 years of industry experience. Starting from the research and development of dental implant surgery systems, the company has expanded its scope to other departments. Its core product, “Yi Zhi Mei,” is the only dental implant surgery real-time navigation system in China approved with a Class III medical device registration certificate. It has been adopted by top-tier dental hospitals such as Peking University School of Stomatology, Wuhan University School of Stomatology, and West China School of Stomatology, achieving stable and high sales growth over the years.

To date, DCARER has filed more than 40 invention patent applications. On one hand, it is further consolidating its leading position in the stomatology field through its surgical teaching systems and orthodontics business; on the other hand, it is actively promoting the application of its surgical navigation systems in other clinical departments, striving to achieve comprehensive multi-departmental coverage and create synergistic effects.

stated: “We sincerely appreciate the strong support from Hengxu Capital and Huiding Capital for this round of financing. DCARER targets a market gap exceeding RMB 5 billion in the dental implant sector, providing convenient and safe surgical options for implant patients. Our commercially launched dental implant surgery navigation system and oral skills training and real-time assessment system have both reached international leading standards, offering patients higher surgical precision and customized services. In the future, building on the continuous iteration of our existing dental products, DCARER will fully leverage the versatility of its surgical robot platform and strive to become a comprehensive platform-based company.”

Lu Yongtao, Chairman of Hengxu Capital“China’s dental implant market is in a period of rapid growth, with implant demand set to accelerate further under the impact of population aging. Currently, competition in the post-pandemic second half of the dental industry has converged on the digital domain, driving a substantial surge in demand for digital equipment in the Chinese market. As one of the earliest companies to establish a presence in dental digitization, DCARER has successfully built high barriers to entry in both product R&D and market promotion, thereby forming core competitive advantages. The surgical robot that DCARER is striving to develop represents a key focus area for Hengxu in the field of digital healthcare. We look forward to the team’s sustained innovation capabilities and believe that DCARER can become a robotics company with international influence.”

Dr. He Xin, Managing Partner at Huiding Capital“The digitalization of surgery is a prevailing trend. Surgical navigation systems enhance diagnostic and treatment precision for physicians, reduce the learning curve, facilitate minimally invasive procedures, and provide real-time intraoperative feedback, thereby promoting rapid postoperative recovery for patients. DCARER’s products have progressed through the R&D and market introduction phases and are now seamlessly integrated into the entire dental implant workflow, ensuring that clinicians are both willing and able to use them effectively. This marks Huiding Capital’s second collaboration with the DCARER team. We are optimistic about the team’s sustained commercialization capabilities and confident in the company’s product expansion based on its underlying navigation technology. We look forward to an increasing number of dental patients benefiting from the company’s products.”

Hengxu Capital (AMAC Registration No.: P1070270) is the private equity investment platform under Shanghai Automotive Industry Corporation (SAIC Motor, 600104.SH). Leveraging the overall strengths of SAIC Motor, the company aims to maximize investor returns by strategically investing in emerging industries such as advanced manufacturing, healthcare, frontier technologies, and mass consumption, thereby contributing to the development of SAIC Motor’s innovative industrial chain and the enhancement of its mobility ecosystem. Hengxu Capital’s healthcare portfolio includes numerous outstanding enterprises, such as Aier Medical, Anzhiyin Biotechnology, Changfeng Pharmaceutical, Demei Medical, Gaocheng Biotechnology, Meili Weiye, Ribobio, Yahong Medicine, and Weizhuzhuo Biotechnology.

Huiding Investment brings together a team of senior partners from China’s top investment institutions, founded by professionals with extensive experience in startup operations, localization of overseas technologies in China, and deep industry resources. Committed to integrating global medical technology innovations and focusing on the upgrading of China’s healthcare industry, Huiding is dedicated to pooling resources and providing robust support to help Chinese enterprises emerge as industry leaders.